Abstracts tagged "Cardiovascular disease and rheumatoid arthritis (RA)"

Abstract Number: 1211 • 2012 ACR/ARHP Annual Meeting
ANTI-Cyclic Citrullinated Protein Antibodies Induce Inflammation and Oxidative Stress in WHITE Blood CELLS of Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Carlos Perez-Sanchez¹, Patricia Ruiz-Limon¹, Mª Angeles Aguirre², Rosario M. Carretero-Prieto¹, Antonio Rodriguez-Ariza³, Nuria Barbarroja¹, Pilar Font¹, Francisco Martinez², Inmaculada Gomez-Gracia², Mª Jose Cuadrado⁴ and Eduardo Collantes-Estevez², ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: Anti-cyclic citrulinated protein antibodies (anti-CCP) are the most specific autoantibody markers in rheumatoid arthritis (RA) patients. However no previous studies have evaluated their role…
Abstract Number: 829 • 2012 ACR/ARHP Annual Meeting
Subcutaneous Nodules Are Significantly Associated with Cardiovascular Events in Patients with Rheumatoid Arthritis: Results From a Very Large US Registry
Prashant Kaushik¹, Susan P. Messing², Jyoti Arora², George Reed³, Katherine C. Saunders⁴, Jeffrey D. Greenberg⁵ and Joel M. Kremer⁶, ¹Department of Medicine, Sratton VAMC, Albany, NY, ²Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, ³Division of Behavioral and Preventive Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Corrona, LLC., Southborough, MA, ⁵New York Hospital for Joint Disease, New York, NY, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Cardiovascular Disease (CVD) is now recognized to be a major comorbidity of patients with rheumatoid arthritis. Predictors of CVD have been shown to include…
Abstract Number: 71 • 2012 ACR/ARHP Annual Meeting
The Association Between Preclinical Markers for Cardiovascular Disease and Rheumatoid Arthritis-Related Autoantibodies in First-Degree Relatives without Rheumatoid Arthritis
Ryan W. Gan¹, Jan M. Hughes-Austin², Kevin D. Deane³, Elaine M. Urbina⁴, Peter K. Gregersen⁵, Michael H. Weisman⁶, V. Michael Holers⁷ and Jill M. Norris¹, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Epidemiology, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Preventive Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is characterized by systemic inflammation and immune dysregulation, including the presence of autoantibodies and elevated inflammatory markers in subjects with…
Abstract Number: 2539 • 2012 ACR/ARHP Annual Meeting
Fine-Specificity of Anti-Citrullinated Peptide Auto-Antibodies: Associations with Cardiac Structure and Function in Rheumatoid Arthritis
Laura Geraldino-Pardilla¹, Jon T. Giles², Jeremy Sokolove³, William H. Robinson⁴ and Joan M. Bathon⁵, ¹Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁴Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁵Columbia University, New York, NY
Background/Purpose: Despite advancements in rheumatoid arthritis (RA) treatment, standardized mortality rates remain up to 3 times higher than in the general population. Cardiovascular disease (CVD)…
Abstract Number: 2542 • 2012 ACR/ARHP Annual Meeting
The Association Between Inflammatory Markers and Hyperlipidemia and the Risk of Myocardial Infarction in Patients with Rheumatoid Arthritis
Jie Zhang¹, Lang Chen², Elizabeth S. Delzell³, Paul M. Muntner³, William B. Hillegass⁴, Monika M. Safford⁵, Iris E. Navarro² and Jeffrey R. Curtis⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Preventative Medicine, Birmingham, AL, ⁵Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL
Title: The Association between Inflammatory Markers and Hyperlipidemia and the Risk of Myocardial Infarction in Patients with Rheumatoid Arthritis Background/Purpose: Patients with rheumatoid arthritis (RA)…
Abstract Number: 1687 • 2012 ACR/ARHP Annual Meeting
The Risk of Atrial Fibrillation in Patients with Rheumatoid Arthritis Compared to the General Population: A Large Cohort Study
Seoyoung C. Kim¹, Jun Liu² and Daniel H. Solomon³, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: It is well-known that rheumatoid arthritis (RA) is associated with cardiovascular disease such as myocardial infarction. However, little evidence exists on the risk of…
Abstract Number: 1257 • 2012 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis in Hispanic Patients with Rheumatoid Arthritis. Correlation with the Presence of Anti-Oxidized LDL Antibodies and Serum Levels of CD40L
Yurilis Fuentes-Silva¹, Soham Al Snih², Natali Serra-Bonett¹, Juan De Sanctis³ and Martin A. Rodriguez⁴, ¹Rheumatology, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, ²Division of Rehabilitation Sciences, Division of Geriatrics. Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX, ³Immunology, Instituto de Inmunología, Caracas, Venezuela, ⁴Centro Nacional de Enfermedades Reumáticas, Hospital Universitario de Caracas, Caracas, Venezuela
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, associated with an excess of cardiovascular morbidity and mortality due to accelerated atherosclerosis. The appearance of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].